6-Methoxydihydrosanguinarine Suppresses the Proliferation of Non-small Cell Lung Cancer Cells through Elevation of ROS and Activation of IRE1/JNK Signaling

Affiliations

¹ School of Pharmacy (Institute of Pharmaceutical Research), Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
² School of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, 271000, PR China.
³ Center Laboratory, The Second Affiliated Hospital of Shandong First Medical University, Taian, 271000, PR China. fzwang@sdfmu.edu.cn.
⁴ School of Pharmacy (Institute of Pharmaceutical Research), Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China. hrfei@sdfmu.edu.cn.

Xiao Qi et al. Cell Biochem Biophys. 2025.

. 2025 Aug 29.

doi: 10.1007/s12013-025-01850-y. Online ahead of print.

¹ School of Pharmacy (Institute of Pharmaceutical Research), Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
² School of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, 271000, PR China.
³ Center Laboratory, The Second Affiliated Hospital of Shandong First Medical University, Taian, 271000, PR China. fzwang@sdfmu.edu.cn.
⁴ School of Pharmacy (Institute of Pharmaceutical Research), Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China. hrfei@sdfmu.edu.cn.

No abstract available

Keywords: 6-Methoxydihydrosanguinarine; Akt; JNK; NSCLC; ROS; YAP.

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests.

1. Zhang, D., Wang, Y., Yu, P., Sun, J., Li, J., Hu, Y., et al. (2025). Scutellarein inhibits lung cancer growth by inducing cell apoptosis and inhibiting glutamine metabolic pathway. Journal of Ethnopharmacology, 337(Pt 2), 118999. https://doi.org/10.1016/j.jep.2024.118999 - DOI - PubMed
1. Bizuayehu, H. M., Ahmed, K. Y., Kibret, G. D., Dadi, A. F., Belachew, S. A., Bagade, T., et al. (2024). Global disparities of cancer and its projected burden in 2050. JAMA Netw Open, 7(11), e2443198. https://doi.org/10.1001/jamanetworkopen.2024.43198 - DOI - PubMed - PMC
1. Waliany, S., Lin, J. J., & Gainor, J. F. (2025). Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer. Trends Cancer, S2405-8033(25), 00006–8. https://doi.org/10.1016/j.trecan.2025.01.005 - DOI
1. Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., et al. (2022). Cancer treatment and survivorship statistics, 2022. C Ca: A Cancer Journal for Clinicians, 72(5), 409–436. https://doi.org/10.3322/caac.21731 - DOI
1. von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., et al. (2023). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology, 41(23), 3881–3890. https://doi.org/10.1200/JCO.22.02763 - DOI - PubMed